These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 9412888)

  • 1. Coagulation complicating cardiopulmonary bypass in a patient with heparin-induced thrombocytopenia receiving the heparinoid, danaparoid sodium.
    Grocott HP; Root J; Berkowitz SD; deBruijn N; Landolfo K
    J Cardiothorac Vasc Anesth; 1997 Dec; 11(7):875-7. PubMed ID: 9412888
    [No Abstract]   [Full Text] [Related]  

  • 2. Orgaran (Org 10172) for cardiopulmonary bypass in heparin-induced thrombocytopenia: role of adjunctive plasmapheresis.
    Schmahl KS; Ganjoo AK; Harloff MG
    J Cardiothorac Vasc Anesth; 1997 Apr; 11(2):262-3. PubMed ID: 9106004
    [No Abstract]   [Full Text] [Related]  

  • 3. Thrombosis during the use of the heparinoid Organon 10172 in a patient with heparin-induced thrombocytopenia.
    Insler SR; Kraenzler EJ; Bartholomew JR; Kottke-Marchant K; Lytle B; Starr NJ
    Anesthesiology; 1997 Feb; 86(2):495-8. PubMed ID: 9054269
    [No Abstract]   [Full Text] [Related]  

  • 4. Use of danaparoid sodium (Orgaran) as an alternative to heparin sodium during cardiopulmonary bypass: a clinical evaluation of six cases.
    Fernandes P; Mayer R; MacDonald JL; Cleland AG; Hay-McKay C
    Perfusion; 2000 Nov; 15(6):531-9. PubMed ID: 11131218
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Thrombopenia increased by heparin and danaparoid].
    Godet G; Bertrand M; Van de Steen E; Boccara G; Koskas F
    Ann Fr Anesth Reanim; 2001 Jan; 20(1):50-3. PubMed ID: 11234580
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Danaparoid for heparin-induced thrombocytopenia: an analysis of treatment failures.
    Kodityal S; Manhas AH; Udden M; Rice L
    Eur J Haematol; 2003 Aug; 71(2):109-13. PubMed ID: 12890149
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Alternative anticoagulation management strategies for the patient with heparin-induced thrombocytopenia undergoing cardiac surgery.
    Murphy GS; Marymont JH
    J Cardiothorac Vasc Anesth; 2007 Feb; 21(1):113-26. PubMed ID: 17289495
    [No Abstract]   [Full Text] [Related]  

  • 8. Cardiopulmonary bypass with danaparoid sodium and ancrod in heparin-induced thrombocytopenia.
    Kanagasabay RR; Unsworth-White MJ; Robinson G; Bevan D; Farnsworth G; Haxby EJ; Smith EE
    Ann Thorac Surg; 1998 Aug; 66(2):567-9. PubMed ID: 9725413
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Fatal danaparoid-sodium induced thrombocytopenia and arterial thromboses.
    Tardy B; Tardy-Poncet B; Viallon A; Piot M; Mazet E
    Thromb Haemost; 1998 Sep; 80(3):530. PubMed ID: 9759647
    [No Abstract]   [Full Text] [Related]  

  • 10. Danaparoid for cardiopulmonary bypass in patients with previous heparin-induced thrombocytopenia.
    Gillis S; Merin G; Zahger D; Deeb M; Drenger B; Hyam E; Eldor A
    Br J Haematol; 1997 Sep; 98(3):657-9. PubMed ID: 9332322
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Use of danaparoid during cardiopulmonary bypass in patients with heparin-induced thrombocytopenia.
    Olin DA; Urdaneta F; Lobato EB
    J Cardiothorac Vasc Anesth; 2000 Dec; 14(6):707-9. PubMed ID: 11139115
    [No Abstract]   [Full Text] [Related]  

  • 12. Lifesaving citrate anticoagulation to bridge ineffective danaparoid [correction of to bridge to danaparoid] treatment.
    Dworschak M; Hiesmayr JM; Lassnigg A
    Ann Thorac Surg; 2002 May; 73(5):1626-7. PubMed ID: 12022563
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Heparin-induced thrombocytopenia: cross-reactivity between standard heparin, low molecular weight heparin, dalteparin (Fragmin) and heparinoid, danaparoid (Orgaran).
    Ramakrishna R; Manoharan A; Kwan YL; Kyle PW
    Br J Haematol; 1995 Nov; 91(3):736-8. PubMed ID: 8555084
    [TBL] [Abstract][Full Text] [Related]  

  • 14. In vitro cross-reactivity of danaparoid sodium in patients with heparin-induced thrombocytopenia type II undergoing cardiovascular surgery.
    Koster A; Meyer O; Hausmann H; Kuppe H; Hetzer R; Mertzlufft F
    J Clin Anesth; 2000 Jun; 12(4):324-7. PubMed ID: 10960207
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Danaparoid. A review of its pharmacology and clinical use in the management of heparin-induced thrombocytopenia.
    Wilde MI; Markham A
    Drugs; 1997 Dec; 54(6):903-24. PubMed ID: 9421696
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Current treatment concepts in heparin-induced thrombocytopenia].
    Ranze O; Greinacher A
    Dtsch Med Wochenschr; 1999 Jul; 124(28-29):865-73. PubMed ID: 10432950
    [No Abstract]   [Full Text] [Related]  

  • 17. Heparin-induced thrombocytopenia and thrombosis.
    Patel VP; Bong M; Di Cesare PE
    Am J Orthop (Belle Mead NJ); 2007 May; 36(5):255-60. PubMed ID: 17571830
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Heparin-induced thrombocytopenia and thrombosis syndrome: in vivo cross-reactivity with danaparoid and successful treatment with r-Hirudin.
    Keng TB; Chong BH
    Br J Haematol; 2001 Aug; 114(2):394-6. PubMed ID: 11529862
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cardiopulmonary bypass and heparin-induced thrombocytopenia: pitfalls of anticoagulation with danaparoid.
    Kanagasabay R; Unsworth-White MJ; Farnsworth G; Haxby EJ; Smith EE
    J Thorac Cardiovasc Surg; 2000 Aug; 120(2):428-9. PubMed ID: 10917979
    [No Abstract]   [Full Text] [Related]  

  • 20. Orgaran during rotational atherectomy in the setting of heparin-induced thrombocytopenia.
    Hale LP; Smith K; Braden GA; Owen J
    Cathet Cardiovasc Diagn; 1998 Nov; 45(3):318-22. PubMed ID: 9829897
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.